Serum concentrations of valsartan and sacubitrilat, the active metabolite of sacubitril, in patients with heart failure with reduced ejection fraction: results of a pilot cross-sectional study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F25%3AE0111856" target="_blank" >RIV/00843989:_____/25:E0111856 - isvavai.cz</a>

Alternative codes found

RIV/61988987:17110/25:A2603DJW

Result on the web

<a href="https://doi.org/10.1080/17512433.2025.2519644" target="_blank" >https://doi.org/10.1080/17512433.2025.2519644</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/17512433.2025.2519644" target="_blank" >10.1080/17512433.2025.2519644</a>

Result language

angličtina

Original language name

Serum concentrations of valsartan and sacubitrilat, the active metabolite of sacubitril, in patients with heart failure with reduced ejection fraction: results of a pilot cross-sectional study

Original language description

Background: Sacubitril/valsartan is used to treat heart failure. It consists of sacubitril (its active metabolite, sacubitrilat, acts as a neprilysin inhibitor) and valsartan (an angiotensin II type 1 receptor blocker). Research design and methods: In this study, the minimum serum concentrations of valsartan and sacubitrilat were analyzed in patients with heart failure with reduced ejection fraction. Results: Serum concentrations of valsartan ranged from 75 to 11,700 µg/L and of sacubitrilat from 607 to 17,646 µg/L. Wide interindividual variability was observed in the serum concentrations of valsartan and sacubitrilat after administration of the same dose. Patients with NYHA class III used a significantly lower dose per day and per kilogram of body weight than those with NYHA class I/II; however, the measured concentrations of valsartan and sacubitrilat did not differ between the two groups. For both drugs, an inverse correlation was found between the weight-adjusted apparent clearance and serum creatinine and urea concentrations, sacubitrilat levels, and estimated glomerular filtration rate. Conclusions: Valsartan and sacubitrilat concentrations showed wide inter-individual variability at the same dose, which could lead to both toxicity and suboptimal concentrations, with the risk of worsening clinical condition. Patients with reduced cardiac and renal functions are at a higher risk of overdose.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30104 - Pharmacology and pharmacy

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Expert review of clinical pharmacology

ISSN

1751-2433

e-ISSN

1751-2441

Volume of the periodical

18

Issue of the periodical within the volume

6

Country of publishing house

GB - UNITED KINGDOM

Number of pages

10

Pages from-to

397-406

UT code for WoS article

001514360500001

EID of the result in the Scopus database

2-s2.0-105008964128